ARTICLES

Filter  
Active filters 0
Remove
  

Refine your searches by:

Collections
Medicine / Sub specialtie
Biology
Education
Public health
Medicine / Pharmacology
Pure sciences
Research
Social Sciences
Law
Economy
all records (51)

Languages
English
German
Spanish

Countries
Indonesia
USA
Italy
Macedonia
India
South Africa
Bosnia Herzegovina
Pakistan
Canada
Russia
all records (35)

Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
all records (20)

Filter  
 
503  Articles
1 of 51 pages  |  10  records  |  more records»
EGFR-TKI is the first-line therapy for EGFR-mutant patients. Nevertheless, patients will have disease progression (median PFS 10 – 12 months) due to resistance. The treatment options are still limited in developing countries for such cases, thus double-pl... see more

Introduction: Data on the utilisation of epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) and their clinical outcomes in a heterogeneous Pakistani-Asian population have not been previously reported. This manuscript presents the fi... see more

Objective: To investigate the effects of EGFR-TKI combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage-IV lung adenocarcinoma.Methods: This retrospective observational study included 116 patients with stage-I... see more

Various tyrosine kinase inhibitor (TKI) drugs have been widely used as therapy for cancer that has EGFR mutations, or abnormal EGFR activation. However, patients who have a mutation in the gene that activates EGFR only benefit from EGFR-TKI therapy for le... see more

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have been introduced for the treatment of lung cancer, improving progression-free survival, objective response rate, and quality of life. However, TKIs can lead to cutaneous toxicities, including papulopustula... see more

Discovery of the epidermal growth receptor (EGFR) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements has expanded the therapeutic landscape in non-small cell lung cancer (NSCLC). Survival outcomes for patients with these mutations ha... see more

Tyrosine kinase inhibitors (TKIs) telah direkomendasikan oleh National Comprehensive Cancer Network (NCCN) sebagai terapi lini pertama pada pasien non-small cell lung cancer (NSCLC) dengan mutasi EGFR, yaitu gefitinib (generasi pertama) dan afatinib (gene... see more

AIM: the present analysis was carried out with the aim of estimating the clinical impact, expressed in terms of progression free survival (PFS), associated with the use of the combined strategy (tissue biopsy and liquid biopsy) or the tissue strategy in t... see more


1 of 51 pages  |  10  records  |  more records»